Generic and Specialty Pharmaceuticals (TRBC)

FDA declines to approve J&J arthritis drug sirukumab

FDA declines to approve J&J arthritis drug sirukumab

Published 22/09/2017

The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday. [more…]

Native American tribe moves to dismiss Allergan patent case

Native American tribe moves to dismiss Allergan patent case

Published 22/09/2017

A Native American tribe holding patents for drugmaker Allergan Plc (AGN.N) on Friday moved to dismiss a case brought by generic drug company Mylan NV (MYL.O) challenging the patents. [more…]

Costly drugs to weigh on U.S. employers` expenses in 2018: survey

Costly drugs to weigh on U.S. employers` expenses in 2018: survey

Published 18/09/2017

U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat diseases such as cancer, multiple sclerosis and hepatitis C is expected to rise more than 7 percent, according to consultancy firm Mercer. [more…]

Exclusive: FDA plans new compounding pharmacy policy, agency head says

Exclusive: FDA plans new compounding pharmacy policy, agency head says

Published 15/09/2017

The head of the U.S. Food and Drug Administration said on Friday the agency is working on a new policy that would encourage more compounding pharmacies to register under a law enacted in the wake of a deadly 2012 meningitis outbreak linked to one such company. [more…]

U.S. senator slams Allergan patent deal with Native-American tribe

U.S. senator slams Allergan patent deal with Native-American tribe

Published 15/09/2017

U.S. Senator Sherrod Brown said on Friday a deal that drugmaker Allergan Plc made with a Native-American tribe to shield patents "rips off consumers" and cannot "become the new normal." [more…]

France`s Neovacs takes on GSK and AstraZeneca in battle to treat lupus

France`s Neovacs takes on GSK and AstraZeneca in battle to treat lupus

Published 15/09/2017

French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said. [more…]

Insurers lead European shares higher as Hurricane Irma weakens

Insurers lead European shares higher as Hurricane Irma weakens

Published 11/09/2017

European shares rose on Monday, led by insurers as the downgrade of Hurricane Irma in the United States raised the prospect that costs for the industry may be lower than initially feared. [more…]

Roche shares hit by trial flops, fears over biosimilar defense

Roche shares hit by trial flops, fears over biosimilar defense

Published 11/09/2017

Roche shares fell in early trading on Monday after trial failures added to the Swiss drugmaker's challenge of replacing patent-expired medicines with lucrative new drugs. [more…]

Israel`s Teva Pharma appoints Lundbeck`s Kare Schultz as CEO

Israel`s Teva Pharma appoints Lundbeck`s Kare Schultz as CEO

Published 11/09/2017

Teva Pharmaceutical Industries Ltd named H Lundbeck A/S Chief Executive Kare Schultz as its new CEO and president on Monday, as it struggles with heavy debts and fierce competition for its generic drugs in the United States. [more…]

J&J unit ends hepatitis C drug development in crowded market

J&J unit ends hepatitis C drug development in crowded market

Published 11/09/2017

Janssen Sciences Ireland UC, a unit of Johnson & Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies. [more…]